GHK-Cu and the memory experiments
Learning and tissue damage appear together in these experiments. The behavioural tasks give the memory question a concrete test.
The experiment in aged mice
The 2023 ageing-mouse preprint tested 20-month-old C57BL/6 mice. The animals received free GHK intranasally at 15 mg/kg daily for eight weeks. Compared with saline controls, treated mice performed better in the Y-maze, a spatial-memory task, and the Box-maze, a learning task.
The accompanying tissue measurements gave the result more substance for me. NFL-1, associated with axonal damage, was lower in both sexes. MCP-1, an inflammatory marker, was lower in female frontal cortex. That sex-specific result deserves its qualifier every time it is mentioned.
An animal learning a task offers a useful companion to a tissue measurement. Here the behaviour and injury markers moved in an encouraging direction. The study still awaits full peer review in the record described here, and its result needs replication by another team.
The 5xFAD mouse experiment
The second 2023 preprint studied 5xFAD mice, a transgenic Alzheimer's-disease model. These mice received intranasal GHK at 15 mg/kg three times weekly for twelve weeks. The authors reported better Y-maze and Box-maze performance, reduced amyloid plaque burden in frontal cortex and hippocampus, and decreased MCP-1.
An ageing mouse and a mouse engineered to develop Alzheimer's-like pathology answer different questions. The parallel behavioural results make the pair worth following, though the same team produced both preprints. They provide no human neurological trial and establish no treatment for Alzheimer's disease.
A quieter headline attached to a successful repeat would suit me very well. Reproducing a useful task result seems a better next step than multiplying claims about rejuvenation.
Copper and zinc around cultured nerve cells
The 2024 Metallomics study examined free GHK in cultured neurons, microglia and astrocytes. Copper and zinc were provoking protein aggregation and cell death. GHK bound extracellular metal and limited its accumulation inside cells, preventing those harmful changes in the experimental systems.
Microglia and astrocytes are support cells of the nervous system; this was a culture experiment involving them, as well as neurons. Applying a peptide directly to cells gives it access that a treatment would have to achieve inside a body.
The free peptide’s role surprised me: the useful action involved collecting excess metal outside the cell. Whether that explains any of the mouse-memory findings remains an open mechanistic question.
Modified GHK in chemical assays
Another 2023 paper attached biotin to GHK and examined the modified peptide and its copper complex. In biochemical, cell-free assays, they inhibited copper-induced ascorbate oxidation and protected against amyloid-beta/acrolein adduct chemistry.
Those experiments concern chemical reactions associated with neurodegeneration. The attachment changes the molecule, and the assays supply no behavioural outcome. The modification makes an interesting chemical experiment that needs biological follow-up. A skin ingredient, a modified peptide and a memory result cannot simply share one conclusion.
Rat behaviour
The neurological literature also includes anxiety-like behaviour in rats exposed to GHK and analogues, and a separate pain-induced aggression experiment in rats. These widen the behavioural questions without establishing effects on human anxiety, pain or memory.
The 2018 gene-data analysis is broader still. Its large-scale expression patterns came largely from database work. The popular '~4,000 genes' figure extrapolates beyond a table containing about 2,100 genes at the stated threshold. Expression changes need protein-level validation in living systems.
My questions converge on the mazes. Human studies, distribution measurements and replication would be needed before that curiosity could justify a clinical claim. The full reading list includes the older skin and wound studies alongside these neurological papers.